News
September 3, 2020 – Banner Life Sciences Announces BAFIERTAM, a Novel Oral Fumarate Treatment for Relapsing Forms of Multiple Sclerosis, is Now Available in the U.S.
View full release as a pdf here:
July 16, 2020 – Banner Life Sciences Announces Commercial Launch of BAFIERTAM, a Novel Oral Fumarate Treatment for Relapsing Forms of Multiple Sclerosis
View full release as a pdf here:
April 30, 2020 – Banner Life Sciences Announces Final FDA Approval of BAFIERTAM for Multiple Sclerosis
View full release as a pdf here:
April 21, 2020 – Banner Life Sciences Receives Favorable Appellate Court Decision in Biogen Patent Infringement Dispute
View full release as a pdf here:
January 09, 2020 – Banner Life Sciences Receives Favorable Ruling Against Biogen in Patent Infringement Challenge
View full release as a pdf here:
July 23, 2019 – Banner Life Sciences Announces First Subject Enrolled in Randomized, Double-Blind Head-to-Head Study of Bafiertam and Tecfidera for Comparative Assessment of GI Tolerability
View full release as a pdf here:
January 02, 2019 – Banner Receives FDA Tentative Approval for BAFIERTAM for the Treatment of Relapsing Forms of Multiple Sclerosis
View full release as a pdf here:
Events
MS Virtual 2020
8th Joint ACTRIMS/ECTRIMS Meeting
September 11-13, 2020